Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
9.5.2023 09:00:00 EEST | Business Wire | Press release
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services and Emerson Announce a Global Cooperation and Strategic Engagement to Drive Innovation in Engineering Excellence12.5.2026 12:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital and Engineering R&D services, today announced a strategic global partnership with Emerson (NYSE: EMR), a global automation leader and provider of advanced test and measurement solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511346343/en/ L&T Technology Services and Emerson announce strategic global partnership. Seen in the picture: Senior leaders and delegates from L&T Technology Services and Emerson’s Test & Measurement business, including the NI leadership team. Under this engagement, LTTS will serve as a global System Integrator and technology development partner, supporting the design, deployment and lifecycle enablement of advanced systems engineering platforms across industries. The partnership also introduces joint engagement approaches for customer projects, positioning LTTS as a key system integration partner for the NI tes
Goldman Sachs Alternatives Acquires FGI Worldwide12.5.2026 12:00:00 EEST | Press release
FGI Worldwide LLC (“FGI” or the “Company”), a leading provider of working capital financing and trade credit insurance solutions, today announced it has been acquired by the Private Equity business within Goldman Sachs Alternatives. Over its 25-year history, FGI has established a strong reputation as a leader and innovator in asset-based lending and risk mitigation, specializing in multi-jurisdictional working capital solutions that support businesses with flexible financing to drive domestic and global expansion. The acquisition enables FGI to accelerate its growth and expand its suite of financing, risk and Insurtech solutions for clients. In conjunction with the transaction, Sami Altaher, Co-Founder and President of FGI, succeeds David DiPiero as Chief Executive Officer, marking the next chapter in the Company’s evolution. “We are grateful to our team, customers, partners and investors who have made this milestone possible,” said Altaher. “I am incredibly proud of what we have built
Kept Alive by ECMO Until Heart Transplant: Sahara Romero's Story of Survival and Recovery, with ECMOlife by Eurosets12.5.2026 11:45:00 EEST | Press release
“Now, for the first time in years, I can live without constantly fearing something could go wrong.” That's how Sahara Romero told her story, presented at the EuroELSO Congress in Dublin (6-8 May), dedicated to lifesaving extracorporeal therapies. Hers is a remarkable journey back to life, where clinical expertise and advanced life-support technologies came together to radically change her fate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511305446/en/ Antonio Petralia, CEO of Eurosets; Sahara Romero, patient; dr. Mario Andrés Mercado Díaz, Intensive care specialist at the Clínica Shaio in Bogotá; Estefanía Giraldo Bejarano, specialist ECMO nurse at the Clínica Shaio in Bogotá Sahara has lived with a serious heart condition since early adolescence. The first signs of heart failure appeared when she was eleven. “When I was doing simple activities, like gymnastics lessons, I got very tired and experienced pain in my chest
New Research From Infobip Finds Disconnected Data and Systems Prevent Brands From Automating Customer Journeys at Scale12.5.2026 11:39:00 EEST | Press release
Global AI-first cloud communications platform Infobip’s 2026 Customer Experience (CX) Maturity Report reveals a widening gap between communications infrastructure investment and CX performance. With ever-increasing customer expectations, achieving CX maturity is the goal for major global brands. This hinges on how well brands can build experiences on mobile channels. There is a fundamental difference between a simple fraud alert on SMS and a two-way WhatsApp chat that allows customers to act immediately. While 96% of brands automate customer interactions in some way, few are delivering a seamless experience. Only 58% of brands say their channels are fully in sync, and 60% have centralized storage of customer data. But looking closer, only 27% use an orchestration platform, and 50% of brands say their tools are fully API-ready. This means half of brands struggle with connecting tools and data and many don't use a unified platform to build truly seamless experiences. This fragmentation i
Rerouting Alone Could Cost Airlines $8 Billion This Summer, New i6 Group Data Shows12.5.2026 11:00:00 EEST | Press release
Airlines flying European long-haul routes are facing a fuel cost penalty that could exceed $8 billion between May and August 2026, according to a new operational data report released today by i6 Group, a global leader in integrated aviation fuel management technology. The report, “Middle East Conflict: Summer 2026 Outlook,” draws on real fueling transactions captured at nearly 300 airports worldwide by i6's Fusion6 platform and provides insight into the costs of the conflict so far and how it might impact summer travel, based on actual fuel supply and into-plane uplift data. Key Findings $5.6 billion – $8.4 billion: Projected industry-wide rerouting fuel cost, May–August 2026 62.2%: Increase in European airport fuel book stocks (April 2026 vs. April 2025) 415,373 tons: Additional CO2 generated monthly from rerouting in the i6 network alone, or the equivalent of nearly 6,000 extra London–New York round-trip flights per month "The data captures what airlines are paying to fly around clos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom